Literature DB >> 12763141

Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts.

Pieter K Wierenga1, Rita Setroikromo, Gera Kamps, Harm H Kampinga, Edo Vellenga.   

Abstract

OBJECTIVES: In autologous stem cell transplantation contamination of the graft with malignant cells is frequently noticed and necessitates the use of in vivo or in vitro purging modalities. The hematopoietic recovery after transplantation depends on the number of stem and progenitor cells in the transplant. Therefore, in the present study the effects of hyperthermic treatment on the human normal and acute myeloid leukemic (AML) stem cell compartment were investigated.
METHODS: Normal bone marrow and AML blasts were heat treated up to 120 minutes at 43 degrees C. The surviving fractions of the different stem cell subsets were determined using in vitro methylcellulose and cobblestone area-forming cell (CAFC) clonogenic assays, as well as the in vivo NOD/SCID repopulating assay. The leukemic nature of the colonies from AML cells was confirmed by RT-PCR analysis. In order to increase the therapeutic index of the hyperthermic purging modality, the heat treatment was preceded by a 3-hour incubation at 37 degrees C with the ether lipid ET-18-OCH(3) (25 microg/mL).
RESULTS: It could be demonstrated that normal progenitor cells are far more resistant to hyperthermia than leukemic progenitor cells (56%+/-7% vs 9.9%+/-2.6% survival after 60 minutes at 43 degrees C, respectively). Furthermore, normal hematopoietic stem cells appear to be extremely resistant to the heat treatment (94%+/-9% survival after 60 minutes at 43 degrees C). In contrast, in the leukemic stem cell compartment no significant differences in heat sensitivity between the stem cells and progenitor subsets could be observed (12.3%+/-2.9% vs 9.9%+/-2.6% survival after 60 minutes at 43 degrees C, respectively). The combined treatment resulted in a survival for normal progenitor and stem cells of 32%+/-6% and 85%+/-15% after 60 minutes at 43 degrees C, respectively. Under these conditions the number of leukemic stem cells was reduced to 1%+/-0.3%. After 120 minutes at 43 degrees C, no AML-colonies could be detected anymore.
CONCLUSIONS: Our data demonstrate that leukemic stem cells have an increased hyperthermic sensitivity compared to their normal counterparts and that this difference can be further increased in combination with ET-18-OCH(3). These striking differences in heat sensitivity warrant the use of hyperthermia as a clinically applicable purging modality in autologous stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763141     DOI: 10.1016/s0301-472x(03)00049-3

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

Review 1.  A primitive cell origin for B-cell precursor ALL?

Authors:  C V Cox; A Blair
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

2.  Heat shock proteins and Bcl-2 expression and function in relation to the differential hyperthermic sensitivity between leukemic and normal hematopoietic cells.

Authors:  R Setroikromo; P K Wierenga; M A W H van Waarde; J F Brunsting; E Vellenga; H H Kampinga
Journal:  Cell Stress Chaperones       Date:  2007       Impact factor: 3.667

3.  MYC and PIM2 co-expression in mouse bone marrow cells readily establishes permanent myeloid cell lines that can induce lethal myeloid sarcoma in vivo.

Authors:  Su Hwa Jang; Hee Yong Chung
Journal:  Mol Cells       Date:  2012-07-26       Impact factor: 5.034

4.  It's Getting Hot in Here: Targeting Cancer Stem-like Cells with Hyperthermia.

Authors:  Haidong Huang; Kevin Yu; Alireza Mohammadi; Efstathios Karanthanasis; Andrew Godley; Jennifer S Yu
Journal:  J Stem Cell Transplant Biol       Date:  2017-12-29

5.  Role of stem cells in cancer therapy and cancer stem cells: a review.

Authors:  Jayesh Sagar; Boussad Chaib; Kevin Sales; Marc Winslet; Alexander Seifalian
Journal:  Cancer Cell Int       Date:  2007-06-04       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.